This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Since the first trials using antiplatelet agents in ischemic stroke and transient ischemic attack (TIA), there has been a consistent difficulty in balancing the benefit of a reduction of recurrent cardiovascular disease outcomes (ischemic stroke and myocardial infarction) with the risk of bleeding.1-4 This had also been an issue in acute stroke trials evaluating the effectiveness of anticoagulation and antiplatelet agents.5,6 For decades, monotherapy remained the standard of care for secondary prevention in most patients with acute ischemic stroke, but observational studies enrolling patients with TIA and minor stroke showed a high risk of recurrence at 90 days, prompting trials with dual antiplatelet agents in these patients. The publication of 3 trials demonstrating a reduction in the risk of stroke has changed our use of dual antiplatelet agents in patients with TIA and minor stroke. In these trials, each with different inclusion criteria, different drug combinations were used for different lengths of time: (1) CHANCE: clopidogrel and aspirin for 21 days, followed by clopidogrel alone for 69 days4; (2) POINT: clopidogrel and aspirin for 90 days3; and (3) THALES: ticagrelor and aspirin for 30 days.2 The risk of bleeding was different in each trial. In POINT, in particular, the risk of bleeding increased after 30 days, the same interval when the benefit seemed more muted.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 227
- Received April 19, 2022.
- Accepted in final form May 3, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
